about
Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?The efficacy and safety of statins for the treatment of non-alcoholic fatty liver diseaseOxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisC2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP.Modern approach to the clinical management of non-alcoholic fatty liver diseaseRate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced diseaseRelationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study.Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver DiseaseSimilar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis.Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation.Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillationVitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort studyTotal adiponectin is inversely associated with platelet activation and CHA₂DS₂-VASc score in anticoagulated patients with atrial fibrillation.Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review.Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition.Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis.Nox-2 up-regulation and platelet activation: Novel insights.Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.ATHEROTHROMBOSIS AND OXIDATIVE STRESS: MECHANISMS AND MANAGEMENT IN ELDERLY.The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review.Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis.Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study.Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia.Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.Under-prescription of statins in patients with non-alcoholic fatty liver disease.Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.Short-term in vivo modifications of platelet NADPH oxidase 2 (NOX2) and prostaglandin F2α in HIV-1 patients on abacavir-based therapies.Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects.Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors.
P50
Q26776043-3AB5B2FF-BAE5-4A37-B362-142F796423B0Q27002905-F5D62B93-772D-4969-8DE5-DBD85D017640Q28084150-0B8C7F38-1945-4672-BDEC-CE1A536A872AQ33812913-024F5D2E-911A-4D2C-A2C3-0D5CF09C6259Q33886923-F34CBD10-4C77-4660-8361-4762EB39F428Q34100037-15EA7E55-3408-4C75-9484-5D6C0EED7FD7Q35640209-F6548864-EA0B-44D1-9E4B-509EFF8BDD4CQ35947534-6F0BDC55-EBA3-4942-8303-694A3B5B5CD4Q36751392-DD297497-C324-4259-84E8-4995410C68DEQ36956791-3443D1A4-D0F6-4987-8360-0F54CB79BAE0Q37364448-2FA048AE-209B-4CF8-8E0A-2FAA69E6BBFFQ37457432-03CE5B1C-1EF7-475A-8A02-8FF0D053C892Q37457754-CA7778EA-C3FE-46BE-8E13-B34614425DDBQ37639726-CEDA14EA-22F4-4982-A2E9-CA916D66BE9CQ37822450-D1869848-8C20-4ACF-A84E-14AFF244AC93Q38140700-6C80F21F-997F-4053-B67D-242FF22092ADQ38164984-31A24B50-5042-4213-A5A3-76093AE2546FQ38202561-CED67DAC-9D29-4EA4-95BB-CC69E01A57EAQ38409212-802862E9-4B14-4133-AE35-5D0D60802000Q38471149-324C69BF-3D1F-4D33-B4E5-0050F3B77030Q38618541-A08CF83E-40B5-4FB1-BB11-ED33ABF04888Q38641215-0B7E5275-5082-4537-883B-1A61CC7C2377Q38725130-9B2543B8-9815-429F-9CB7-FD80F0AB1210Q38768207-02147027-1022-45AD-97C9-8F03A1250BABQ38799614-E111CB5A-E11C-4292-9792-5915DF9EF13EQ38843749-57F8354E-20D3-4790-9F11-80EDC454B885Q39021448-0B6B3F6D-7C89-42CB-9144-8853C50323D6Q39187283-16DB8778-4270-4C8B-8989-C0E42679AA22Q39438344-E0289B0B-BF15-4777-8097-4481CCB190CEQ40045475-9D917038-6515-48E8-AD78-3A937725A499Q40049884-E5404DCC-638C-4BB3-9BE4-CE2B94EB0F74Q40425158-47D3879D-343B-4F25-A2C8-293F7BB103F8Q40561755-5AD9E30F-A51D-4AD1-A329-9494F152A801Q40595356-B46DA957-37D0-46A9-B7A4-686F73AC3F00Q40680369-CD4878AF-98BE-44D7-9312-004781404A61Q40917241-7A30D596-DD4A-4C53-A13D-B2F31739731FQ40950038-D8DDD49D-4019-446F-AA49-0672E3571FDEQ40992076-0F964D73-E3E1-4072-A040-6C8C748054FFQ41099825-70677CAD-C16C-451C-87E0-FC14E814C80BQ41209308-BA830056-1AED-4804-A89B-5A28F7A81BFE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniele Pastori
@ast
Daniele Pastori
@en
Daniele Pastori
@es
Daniele Pastori
@nl
Daniele Pastori
@sl
type
label
Daniele Pastori
@ast
Daniele Pastori
@en
Daniele Pastori
@es
Daniele Pastori
@nl
Daniele Pastori
@sl
prefLabel
Daniele Pastori
@ast
Daniele Pastori
@en
Daniele Pastori
@es
Daniele Pastori
@nl
Daniele Pastori
@sl
P1053
J-7087-2016
P106
P1153
35741492700
P1960
RvS_4S8AAAAJ
P2038
Daniele_Pastori
P21
P31
P3829
P3835
daniele-pastori
P496
0000-0001-6357-5213